ZYDELIG (Idelalisib) Tablets 100mg

ZYDELIG

Facts of ZYDELIG (Idelalisib) Tablets 100mg ?

  • Medicine Name: ZYDELIG
  • Generic Name: Idelalisib
  • Approval Date: July 23, 2014
  • Company Name: Gilead Sciences, Inc.
  • Available as (Form & Strength): 100 mg and 150 mg Tablets

What are the indications and usage?

Zydelig is a kinase inhibitor indicated for the treatment of patients with:

  • Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.
  • Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.
  • Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies.

Zydelig ®

Generic name: Idelalisib (eye del a LIS ib)

Chemocare.com uses trade names in all descriptions of drugs. Zydelig® is the trade name for the generic chemotherapy drug idelalisib. In some cases, health care professionals may use the generic name idelalisib when referring to the trade drug Zydelig®.

Drug type: Zydelig® is a targeted therapy. It is an oral Phosphatidylinositol 3-kinase inhibitor – (For more detail, see “How this drug works,” below).

What this drug is used for:

Chronic lymphocytic leukemia: Treatment of relapsed chronic lymphocytic leukemia (CLL) (in combination with rituximab) when rituximab alone is appropriate therapy due to other comorbidities.

Follicular B-cell non-Hodgkin lymphoma: Treatment of relapsed follicular B-cell non-Hodgkin lymphoma after at least 2 prior systemic therapies.

Small lymphocytic lymphoma: Treatment of relapsed small lymphocytic lymphoma (SLL) after at least 2 prior systemic therapies.

Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful.